Pipeline

Our DARPin platform has vast applicability across a range of diseases. Explore our pipeline:

Oncology
Discovery Oncology
Virology
Ophthalmology
Candidate
Research
Preclinical
Phase 1
Phase 2
Phase 3
Rights
MP0317 / FAP x CD40: Solid Tumors
Phase 1
MP0533 / CD33 x CD70 x CD123 x CD3: AML
Preclinical
In-house programs
Radio DARPin Therapies: DLL3 and more
Research
Partnered programs
Radio DARPin Therapy Platform: Solid tumors
Preclinical
Virology
Research
Immune Cell Engagers
Research
 
Abicipar1 / VEGF: Wet AMD
Phase 3
Ensovibep2 / Sars-Cov-2: COVID
Phase 2
  1. The Company continues to evaluate potential business opportunities for abicipar, outside of Molecular Partners.
  2. Molecular Partners was informed by Novartis that the Emergency Use Authorization (EUA) application from the U.S. Food and Drug Administration (FDA) for ensovibep was withdrawn effective January 25th, 2023. As previously disclosed, ensovibep is not presently in clinical development.